Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Branch Retinal Vein Occlusion: later-stage trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Branch Retinal Vein Occlusion: 4 US clinical trials tracked, none currently recruiting.
Branch Retinal Vein Occlusion is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Palmetto Retina Center, running 1 of these trials.
Enrollment posture brief
Registry condition branch-retinal-vein-occlusion
OPEN 0 | RECR 0% | LATE 2 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Branch Retinal Vein Occlusion has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Branch Retinal Vein Occlusion on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Branch Retinal Vein Occlusion is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Hoffmann-La Roche
NCT05476926
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
Regeneron Pharmaceuticals
NCT01521559
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Palmetto Retina Center
NCT00406107
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Retina Associates of Florida, P.A.
NCT01247220
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Branch Retinal Vein Occlusion records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Branch Retinal Vein Occlusion trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Branch Retinal Vein Occlusion page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Branch Retinal Vein Occlusion trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Palmetto Retina Center sponsors the most Branch Retinal Vein Occlusion trials on record, review their full trial history before evaluating a specific study. See Palmetto Retina Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Branch Retinal Vein Occlusion condition card totals 4 registered trials; most-linked intervention Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321); top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.